Authors
Maria Madeleine Rüthrich, C Giessen-Jung, S Borgmann, AY Classen, S Dolff, B Grüner, F Hanses, N Isberner, P Köhler, J Lanznaster, U Merle, S Nadalin, C Piepel, J Schneider, M Schons, R Strauss, L Tometten, JJ Vehreschild, M von Lilienfeld-Toal, G Beutel, K Wille, LEOSS Study Group
Publication date
2021/2
Journal
Annals of hematology
Volume
100
Pages
383-393
Publisher
Springer Berlin Heidelberg
Description
Introduction
Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk.
Patients and methods
We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality.
Results
In total, 435 cancer patients were included in our analysis. Commonest …
Scholar articles
MM Rüthrich, C Giessen-Jung, S Borgmann… - Annals of hematology, 2021